AmoyDx® KRAS/NRAS Mutations Detection Kit | 8.01.25402W006/8.01.25402X024

AmoyDx® KRAS/NRAS Mutations Detection Kit | 8.01.25402W006/8.01.25402X024 | Gentaur UK, US & Europe Distribution  

RAS protein is a GTPase and one of the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR). RAS protein transduces signals from membrane-bound receptors via multiple downstream effector pathways and thereby affects fundamental cellular processes, including proliferation, apoptosis, and differentiation. In total, activating KRAS and NRAS mutations occur in 20~50% and 1~6% of colorectal cancer respectively, mainly in exons 2, 3 or 4. The mutation status of the RAS gene is relevant to the primary drug resistance of colorectal cancers treated with anti-EGFR monoclonal antibodies. Patients with wild-type KRAS and NRAS gene could benefit from Erbitux (Cetuximab) or Vectibix (Panitumumab), whereas, the patients with mutant KRAS or NRAS gene show poor response to this treatment. RAS testing is recommended for the selection of colorectal cancer patients to receive anti-EGFR antibody therapy by NCCN Clinical Practice Guideline in Oncology and European Drug Administration Organization.

Testing Procedure